Introduction
In the past several years, the DLC1 (deleted in liver cancer 1) gene, which encodes a ubiquitously expressed Rho GTPase-activating protein (Rho-GAP), has attracted considerable interest because it is frequently downregulated in a variety of tumor types and possesses potent oncosuppressive activity in cell lines derived from several major cancers (Yuan et al., 1998; Durkin et al., 2007a) . Consistent with these observations, DLC1 has recently been confirmed as a bona fide tumor suppressor gene that regulates RhoA in an in vitro/in vivo reconstitution mouse model of hepatocellular carcinogenesis (Xue et al., 2008) . Recent genome-wide sequencing analyses of prostate, colon and pancreatic cancers have also identified missense mutation of DLC1 (Jones et al., 2008; Liao et al., 2008) . DLC1 is the prototype of a multigene family that includes two other closely related genes, DLC2 and DLC3, which have been studied less extensively than DLC1. DLC2 and DLC3 are widely expressed in normal cells and, as is true of DLC1, are also inactivated in several different cancers. Limited comparative analysis between the three DLC genes has suggested that at least one of the DLC genes is expressed in many tumors (Ullmanova and Popescu, 2006; Durkin et al., 2007b) .
The full inhibitory effects on cell growth and tumorigenicity induced by wild-type DLC genes require their Rho-GAP activity, which can negatively regulate RhoA, RhoB, RhoC and, to a lesser degree, CDC42 Wong et al., 2005; Healy et al., 2007; Kawai et al., 2007; Kim et al., 2007; Guan et al., 2008) . Inactivation of DLC1, through genetic and epigenetic changes, may represent the most frequent mechanism for aberrant activation of Rho GTPases in human oncogenesis. However, the function of DLC1 appears to be complex, as analysis of DLC1 mutants in which the Rho-GAP function has been inactivated indicates that Rho-GAP-independent mechanisms may also contribute to the anti-oncogenic activity of DLC1 Healy et al., 2007; Kim et al., 2007; Qian et al., 2007) . Consistent with this hypothesis, DLC1 has a multidomain structure that includes a sterile alpha motif (SAM) near its N terminus, which in other proteins has been implicated in protein-protein interactions, and a steroidogenic acute regulatory-related lipid transfer (START) domain at its C terminus, in addition to the Rho-GAP domain, which is located upstream from the START domain (Yuan et al., 1998) . The presence of these various motifs, together with the Rho-GAP-independent activities, has suggested that DLC1 might interact with other proteins in addition to Rho GTPases. Identification of such interacting partners could enhance our understanding of the mechanisms that regulate the function of DLC1. Thus far, the only additional binding partners that have been clearly identified are members of tensin family, which interact with DLC1 sequences located between the SAM and Rho-GAP domains (Yam et al., 2006; Liao et al., 2007; Qian et al., 2007) . Structure-function analysis of DLC1 demonstrated that suppression of cell migration and anchorage-independent growth by DLC1 in a lung cancer cell line required cooperation between the Rho-GAP activity and tensin binding activity, although the two functions did not depend on each other (Qian et al., 2007) .
To identify other binding partners, a yeast two-hybrid screen with DLC1 was carried out. Here, we report that p120Ras-GAP (Ras-GAP), which is a ubiquitously expressed negative regulator of Ras that is encoded by the Ras-GAP gene (also know as RASA1), was identified by this screen as a novel binding partner for DLC1. We have confirmed that this interaction occurs in mammalian cells, mapped the regions of DLC1 and Ras-GAP that mediate binding and provided data suggesting that Ras-GAP can serve as a negative regulator of the Rho-GAP and tumor suppressor activity of DLC1.
Results

Identification of Ras-GAP as a binding partner of DLC1
In a yeast two-hybrid assay, an interaction was identified between DLC1 and Ras-GAP. This positive result occurred when amino acids 590-880 of human DLC1, which is mainly composed of the Rho-GAP domain, were used as bait to trap N-terminal residues 91-511 of Ras-GAP as prey ( Figure 1A ). To confirm that this interaction also occurs with the endogenous proteins in mammalian cells, we carried out immunoprecipitation and western blotting with extracts from a human hepatocellular carcinoma cell line, SK-Hep1, and a human prostate cancer cell line, DU145, which express high levels of endogenous Ras-GAP and DLC1 proteins. Consistent with the yeast two-hybrid results, complex formation between Ras-GAP and DLC1 was detected in the cell extracts ( Figure 1B ; data shown for SK-Hep1).
Ras-GAP colocalizes with DLC1
To determine the subcellular compartment(s) in which DLC1 interacts with Ras-GAP in mammalian cells, double immunofluorescent staining was performed in SK-Hep1 cells, which as noted above contain endogenous DLC1 and Ras-GAP, and in the DLC1-negative prostate Figure 1C ). By using vinculin as a marker for focal adhesions, it was confirmed that Ras-GAP and DLC1 are colocalized predominantly at focal adhesions (Supplementary Figure 1) .
DLC1 Rho-GAP catalytic domain binds to Ras-GAP SH3 domain Ras-GAP contains multiple domains, including an N-terminal SH3 domain flanked by two SH2 domains, a pleckstrin homology domain and a C-terminal GAP domain ( Figure 1A ; Trahey et al., 1988; Vogel et al., 1988) . The binding region of Ras-GAP identified in the yeast two-hybrid, amino acids 91-511, contains both of the SH2 domains and the SH3 domain. In other proteins, these domains are common docking sites for protein-protein interaction (Mayer and Eck, 1995; Musacchio, 2002; Bradshaw and Waksman, 2002) . Deletion mapping indicated that the SH3 domain was sufficient to bind full-length endogenous DLC1 in SK-Hep1 cells and that the SH2 domains did not interact with DLC1 (Figures 2a and b ). For DLC1, the yeast two-hybrid bait spanned amino acids 590-880, which, as noted above, is primarily composed of the catalytic Rho-GAP domain of DLC1 (amino acids 641-867). Deletion mapping of interaction by this fragment indicated that the DLC1 Rho-GAP catalytic domain SH3 domain of Ras-GAP inhibits DLC1 Rho-GAP activity in vitro To assess the functional relevance of Ras-GAP binding to DLC1, we investigated whether the isolated SH3 or tandem SH2-SH3-SH2 domains of Ras-GAP could affect the GAP activity of the DLC1 Rho-GAP catalytic domain toward RhoA. We used a single-turnover fluorescent assay to measure in real time the hydrolysis of GTP, using purified bacterially expressed proteins. As shown in Figure 3 , the Rho-GAP domain of DLC1 induced a massive increase in the rate of RhoA-GTP hydrolysis. Interestingly, both the isolated SH3 domain and the tandem SH2-SH3-SH2 domains strongly inhibited the Rho-GAP activity, by 15-and 18-fold, respectively (Table 1 ). These observations serve as further confirmation of direct binding between the Ras-GAP SH3 domain and the DLC1 Rho-GAP domain and, more importantly, show that Ras-GAP binding has the functional effect of inhibiting the Rho-GAP activity of DLC1.
Ras-GAP increases RhoA activity and reduces growth suppression We also wished to examine the effects of Ras-GAP on RhoA-GTP (active Rho) and cell growth in a relevant cell line. The above biochemical results predict that the Ras-GAP-mediated inhibition of the DLC1 Rho-GAP activity would be expected to increase the level of active RhoA, which would therefore attenuate the growthsuppressive activity of DLC1. However, this putative biological effect of Ras-GAP on DLC1 could be obscured by the well-known growth inhibitory effects of Ras-GAP that are mediated by its negative regulation of wild-type Ras (Zhang et al., 1990; Tocque et al., 1997) . We therefore studied the effects of Ras-GAP in a cell line that contains mutationally activated Ras, because mutant Ras is resistant to negative regulation by Ras-GAP, which means that the effects of Ras-GAP in such a line should be Ras independent. To this end, HCT15 was identified as a colon carcinoma cell line that contains mutant Ras (Gly12-H-Ras-Ser; Supplementary  Figure 2 ), as well as low levels of endogenous Ras-GAP (Shankavaram et al., 2007) , high levels of DLC2 and undetectable levels of DLC1 (data not shown).
To determine whether the interaction of DLC1 with Ras-GAP would influence the regulation of RhoA, we examined the effect of Ras-GAP on RhoA activity in HCT15 cells, as determined by a pull-down assay using the isolated Rho-GTP binding domain of Rhotekin, which associates preferentially with active RhoA-GTP. Stable transfection of these cells with Ras-GAP significantly increased its expression and RhoA activity compared with the vector control (P ¼ 0.017; Figure 4a ). We also verified that the level of active Ras was not altered by the Ras-GAP in HCT15 cells (Figure 4b ). The effect of Ras-GAP on the growth-suppressing activity of DLC1 was also examined. Previous studies observed an antiproliferative effect of DLC1 in other cancers, and recent data showed in addition that suppression of DLC1 by RNA interference promoted cell growth and migration in a human colon carcinoma cell line (Jin et al., 2008) . Consistent with these observations, we found that adenovirus-mediated overexpression of DLC1 induced a substantial reduction in growth compared with that of parental colon carcinoma cells infected with the control adenovirus that expresses LacZ (Figure 4c ). By contrast, adenovirus-mediated expression of DLC1 in cells stably transfected with Ras-GAP resulted in approximately four times as many cells after 1 week in culture, compared with the cells expressing only DLC1, indicating that Ras-GAP can antagonize Figure 3 Effect of Ras-GAP SH3 domain on the catalytic activity of DLC1 Rho-GAP. Bacterially expressed DLC1 Rho-GAP domain and the SH3 and tandem SH2-SH3-SH2 domains of Ras-GAP were purified for in vitro analysis of Rho-GAP activity. Purified RhoA was preloaded with GTP, and GTP hydrolysis was monitored with a single-turnover assay in which a fluorescent PBP (phosphate-binding protein) undergoes an increase in fluorescence upon binding free inorganic phosphate. 
Discussion
In this study, we have generated evidence that leads us to conclude that Ras-GAP attenuates the tumor suppressor activity of DLC1 by interfering with the Rho-GAP activity of DLC1. We found that endogenous levels of the DLC1 tumor suppressor protein form a stable complex with endogenous Ras-GAP, and that there is extensive colocalization of the two proteins by immunomicroscopy. The interaction was mapped to the Rho-GAP catalytic domain of DLC1 and the SH3 domain of Ras-GAP. We showed that this interaction can inhibit the Rho-GAP activity of DLC1 in vitro. Furthermore, overexpression of Ras-GAP, in a cell line that harbored mutant Ras and thus was resistant to the negative regulation of Ras by Ras-GAP, increased the level of endogenous active Rho and antagonized the growth-suppressive effects of DLC1. Although the current analysis has been confined to the interaction between the Ras-GAP and the Rho-GAP domain of DLC1, we speculate that a similar interaction may occur between the other two DLC family members, DLC2 and DLC3, whose Rho-GAP domains share 80 and 71%, respectively, with this region of DLC1. The regulation of DLC1 by Ras-GAP has several distinct features. A prior study from one of our laboratories suggested that DLC1 has an intramolecular mechanism responsible for limiting its catalytic activity, as the SAM domain of DLC1 appears to function as an inhibitor of its Rho-GAP activity (Kim et al., 2008) . The current observations with DLC1 and Ras-GAP show that an intermolecular mechanism can also regulate this activity. In addition, the functional consequences that result from the binding of DLC1 with Ras-GAP differ from those of DLC1 binding to members of the tensin family ( Figure 5 ). That interaction, although it contributes to the physiological activity of DLC1, is not associated with regulation of the Rho-GAP activity of DLC1 (Qian et al., 2007) . Thus, at least two different types of protein interactions with DLC1 exist. It seems possible that DLC1 tumor suppressor function may ultimately be found to depend on its interaction with other proteins in a complex network. The DLC1 amino acids that mediate the interaction with the Ras-GAP SH3 domain may be unusual. SH3 domains contain well-conserved aromatic amino acids that most commonly recognize proline-rich sequences, typically PxxP, in its interacting proteins (Li, 2005) . However, none of the five PxxP motifs identified by the SH3-Hunter software (Ferraro et al., 2007) in DLC1 were located in the binding region (aa 590-880; Supplementary Figure 3) . This observation indicates that the binding of the DLC1 Rho-GAP catalytic domain to the Ras-GAP SH3 domain is not mediated through such a proline-rich motif, thus suggesting atypical peptide recognition. This feature may be attributable to structural differences between the Ras-GAP SH3 domain and other SH3 domains (Ross et al., 2007) , as three important residues (Leu288, Val332 and Leu335) that participate in the docking of proline-rich motifs (PxxP) are not conserved in Ras-GAP (Ross et al., 2007) . Indeed, Ras-GTPase-activating protein SH3-domain-binding protein (G3BP) does not use its several proline-rich motifs to bind Ras-GAP (Kennedy et al., 2001) .
Ras-GAP has been implicated previously in cross talk between Ras and Rho. p190Rho-GAP, which is another major regulator of cellular Rho protein, binds simultaneously to the two SH2 domains of Ras-GAP through its two closely linked tyrosine-containing peptides (Bryant et al., 1995) . Although this binding does not appear to alter the enzymatic Rho-GAP activity of p190Rho-GAP, complex formation between p190Rho-GAP and Ras-GAP is believed to increase the negative regulation of Rho by mediating the Ras-GAP-dependent translocation of complexed p190Rho-GAP to the plasma membrane (Bradley et al., 2006) . Thus, the Ras-GAP-induced effects on Rho that are mediated through its association with p190Rho-GAP are the opposite of the Ras-GAP effects on Rho that are mediated by its interaction with DLC1. As DLC1 is localized primarily to focal adhesions, whereas p190Rho-GAP may be diffusely cytoplasmic or associated with the plasma membrane, the opposite activities of Ras-GAP toward these two Rho regulators might be related to their distinct subcellular localization and imply that p190Rho-GAP and DLC1 mediate different physiological functions. The latter possibility is supported by the observations that genetic disruption of p190Rho-GAP or DLC1 in the mouse results in distinct phenotypes associated with postnatal and embryonic lethality, respectively (Brouns et al., 2000; Durkin et al., 2005) .
Other studies have also implicated the SH3 domain of Ras-GAP in cross talk with Rho, where it could be relevant that p190Rho-GAP binding induces Ras-GAP to undergo a conformational change that results in a 100-fold increase in the accessibility of the SH3 domain (Hu and Settleman, 1997) . A brain-specific Rho-GAP with various names, including p200Rho-GAP, Grit, Rics and p250 GAP, has been shown to interact with Ras-GAP by binding the SH3 domain of Ras-GAP (Shang et al., 2007) . In addition, a monoclonal antibody that binds the Ras-GAP SH3 domain can block neurite outgrowth of PC-12 cells stimulated with lysophosphatidic acid and prevent the formation of actin stress fibers in Swiss 3T3 cells stimulated with growth factors (Leblanc et al., 1998) . Importantly, the inhibitory effects of the antibody could be overcome by activated Rho, but not by activated Ras, implying that the antibody had induced a reduction in Rho activity. Although it is unknown whether these effects depend on DLC, they are compatible with the scenario that the monoclonal antibody had increased the Rho-GAP activity of DLC by blocking the interaction with Ras-GAP. As suggested from the above studies, the function of Ras-GAP is complicated. The function of its C terminus, which contains the Ras-GAP catalytic domain, as a negative regulator of wild-type Ras is well established, but the N terminus of Ras-GAP, which contains the SH2 and SH3 domains, has been implicated in effectors functions, which could be Ras independent (Clark et al., 1997; Tocque et al., 1997; Abdellatif et al., 1998) .
Our studies suggesting that Ras-GAP can promote the growth of cells containing mutant Ras add to a growing body of evidence suggesting that Ras-GAP Figure 5 Regulation of DLC1 activity. The schematic model illustrates the interacting partners of DLC1, tensin and Ras-GAP, and their functional effects on the tumor suppressor activity of DLC1. Members of tensin family recruit DLC1 to focal adhesions through the consensus sequence SIY 442 DNV, shared by all three DLC proteins, thus contributing to the physiological activity of DLC1. The SH3 domain of Ras-GAP binds to Rho-GAP domain of DLC1 and attenuates the tumor suppressor activity of DLC1 by interfering with the Rho-GAP activity of DLC1. TSG, tumor suppressor gene; ( þ ), increases; (À), inhibits. might represent a valid therapeutic target. Approximately 30% of all tumors carry a mutant Ras (Forbes et al., 2006) , and there is a particular need for improved therapeutic approaches to tumors with mutant Ras, which are often associated with treatment resistance and poor prognosis (Baselga and Rosen, 2008) . Several activities that may depend on the SH3 domain of Ras-GAP could promote growth and/or be anti-apoptotic, including the activation of survivin and Akt and the inactivation of DLC (Gigoux et al., 2002; Yue et al., 2004; Zhou et al., 2004) . The monoclonal antibody that binds the SH3 domain of Ras-GAP can be proapoptotic (Leblanc et al., 1999) . Similar results have also been seen, in tumor lines with mutant Ras, and even one with wild-type Ras, with an aptamer that specifically binds the Ras-GAP SH3 domain (Pamonsinlapatham et al., 2008) . We speculate that the observed proapoptotic activity may result from interfering with the multiple pathways that appear to be inhibited by blocking the binding activity of the SH3 domain, which therefore make it an attractive molecular target for therapeutic intervention.
Materials and methods
Cell culture and transfection
The human SK-Hep1 (hepatocellular carcinoma), PC-3 (prostate carcinoma), HCT15 (colon carcinoma) and HEK293 (embryonic kidney) cell lines were obtained from ATCC (Manassas, VA, USA). SK-Hep1 cells were cultured in Dulbecco's modified Eagle's medium, and the others in RPMI 1640 medium containing 10% (v/v) fetal calf serum at 37 1C in a humidified 5% CO 2 atmosphere. Transient transfection was carried out with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Stable HCT15 clones expressing Ras-GAP were generated by transfection with Lipofectamine 2000 followed by selection with neomycin.
Yeast two-hybrid assay
The yeast two-hybrid screen was performed by Myriad Genetics (Salt Lake City, UT, USA). A DLC1 cDNA fragment encoding a 291-amino-acid polypeptide (residues 590-880) was subcloned in-frame into pGBT.superB containing the GAL4 DNA-binding domain. A human lung cDNA library was screened with the PNY 200 yeast strain according to the manufacturer's instructions. The bait and prey plasmids were cotransformed into naive yeast strain to confirm the interaction, and analysed by DNA sequencing.
Vector construction and adenovirus production An adenovirus encoding the DLC1 cDNA was prepared as previously described (Guan et al., 2008; Zhou et al., 2008) . The Ras-GAP-encoding plasmid was kindly provided by Alex Papageorge (NCI, Bethesda, MD, USA). Bacterial expression vectors encoding glutathione S-transferase (GST) fusion proteins containing the Ras-GAP SH3 domain were provided by Jeffrey Settleman (MGH, Charlestown, MA, USA). To narrow the domain of DLC1 that interacts with Ras-GAP, a series of vectors for expressing truncated fragments of DLC1 (residues 590-641, 641-847, 798-880, 847-880 and 590-880) with an N-terminal V5 tag was constructed. Briefly, cDNAs corresponding to these truncated fragments were subcloned into the pENTER/D-TOPO vector (Invitrogen), and the cDNA inserts were then transferred into the pcDNA3.1/nV5-DEST vector by means of the Gateway system using LR Clonase (Invitrogen). All constructs were verified by DNA sequencing.
Immunoprecipitation and immunoblotting DLC1-positive SK-Hep1 cells or HEK293 cells transiently transfected with truncated DLC1 fragments with the V5 tag were collected and lysed in immunoprecipitation lysis buffer. Anti-DLC1 (H260) polyclonal antibodies, anti-Ras-GAP (B4F8) monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-V5 monoclonal antibodies (Invitrogen) and protein G-Sepharose slurry (Zymed Inc., San Francisco, CA, USA) were added into precleared cell lysates. Immunoprecipitates were washed and subjected to immunoblotting analyses using the antibodies to DLC1 or Ras-GAP.
Pull-down assay
Agarose-conjugated Ras-GAP N-SH2 (residues 175-274), SH3 (residues 277-346) or C-SH2 (residues 343-442) domain proteins with the GST tag were purchased from Santa Cruz Biotechnology. SK-Hep1 cells and truncated fragments of DLC1 (residues 641-847) with an N-terminal V5 tag transiently transfected into HEK293 cells were lysed, and cell lysates were precleared. Ten micrograms of each agarose-conjugated recombinant protein was added to 500 mg of total cell lysate, respectively, and rotated at 4 1C for 4 h. The pellets were then washed with lysis buffer and collected for immunoblotting analysis using the anti-DLC1 polyclonal antibodies, anti-V5 antibody or anti-GST antibody (Pierce, Rockford, IL, USA).
Confocal microscopy PC-3 cells infected with Ad-DLC1 at 50 MOI (multiplicity of infection) and SK-Hep1 were grown on a glass chamber and incubated at 37 1C for 48 h. Cells were fixed and permeabilized in ice-cold methanol and then blocked with 1% bovine serum albumin at room temperature. Coverslips were stained with the anti-DLC1 (H260), anti-Vinculin (H300) or anti-Ras-GAP (B4F8) antibody (Santa Cruz Biotechnology) followed by anti-rabbit Alexa 488-or anti-mouse Alexa 568-conjugated secondary antibody (Molecular Probes Inc., Eugene, OR, USA) and examined by a Zeiss 510 confocal microscopy.
In vitro Rho-GAP assay The in vitro GAP activity of DLC1 was measured with a fluorescence-based technique as previously described (Healy et al., 2007) . This assay uses a fluorescent labeled, phosphatebinding protein (PBP; provided by Martin Webb, National Institute for Medical Research, Mill Hill, London) sensor. A change of PBP conformation, caused by binding to a single Pi, is coupled to a measurable increase in fluorescence of the fluorophore (Shutes and Der, 2005) . Briefly, RhoA GSTfusion protein, the Rho-GAP domain of DLC1 (residues 609-878), and the SH3 and SH2-SH3-SH2 domains of Ras-GAP were purified from BL-21 Escherichia coli cells by glutathione Sepharose 4B chromatography. The RhoA-GST protein was preloaded with GTP. Hydrolysis assays were initiated by adding 30 nM DLC1 Rho-GAP domain in an assay buffer. A molar excess (1 mM) of SH3 or SH2-SH3-SH2 domains of Ras-GAP was also added to the DLC1 Rho-GAP domain. The increases in Pi production from GTP hydrolysis were measured with a SpectraMAX Gemini (Molecular Devices) spectrofluorimeter by checking increases in fluorescence (l ex ¼ 425 nm and l em ¼ 465 nm). Hydrolysis curves were fitted to a single-exponential function with GraphPad Prism software to determine the times to 50% hydrolysis.
RhoA activity analysis Active RhoA was measured using an enzyme-linked immunosorbent assay-based RhoA activation assay kit (Cytoskeleton, Denver, CO, USA) according to the manufacturer's protocol. Briefly, after 24 h of serum starvation and 30 min of calpeptin stimulation, cells were lysed, and the protein concentration was determined. Thirty micrograms of cell lysate from each sample was incubated in microwells coated with the isolated Rhotekin Rho-binding domain, and active RhoA was measured using indirect immunodetection followed by a colorimetric reaction measured by absorbance at 490 nm.
MTT assay Cells were seeded in 96-well plates and infected with Ad-DLC1 or Ad-LacZ at 50 MOI. The MTT (3-(4,5-dimethylthiazol2yl)-2,5-diphenyltetrazolium bromide) (Roche, Indianapolis, IN, USA) assay was used to test cell proliferation as previously described (Guan et al., 2008) .
Ras activity assay Ras activity was determined using an EZ-Detect Ras Activation Kit (Pierce) according to the manufacturer's protocol. Briefly, 500 mg of cell lysate from each sample was incubated with a SwellGel Immobilized Glutathione Disc and GST-Raf-RBD for 1 h at 4 1C, and pellets were washed with lysis buffer and boiled in sample buffer. Samples were then subjected to western blotting with anti-Ras antibody (Pierce).
